Stuttgart - Delayed Quote EUR

CytomX Therapeutics Inc (6C1.SG)

0.8410

-0.0885

(-9.52%)

At close: January 10 at 9:35:50 PM GMT+1

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 p.m. PT. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com.

GlobeNewswire 3 days ago

CTMX
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 4 days ago

CTMX
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 - - Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025 - - Revised focus and associated cost and headcount reductions expected to extend cash runway into the second quarter of 2026 - - Company to pre

GlobeNewswire 5 days ago

CTMX
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.

Zacks 5 days ago

KOD

VNDA

CTMX
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.

Zacks 8 days ago

ARQT

CSTL

CTMX
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

Zacks 8 days ago

MSB.AX

CSTL

CTMX
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Zacks 8 days ago

CAPR

CSTL

SPRO
Neumora Stock Hits Record Low on Depression Drug Study Failure

NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.

Zacks 8 days ago

NMRA

CSTL

SPRO
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.

Zacks 9 days ago

CSTL

CTMX
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.

Zacks 9 days ago

VSTM

CTMX

CSTL
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks 26 days ago

CTMX
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.

Zacks 30 days ago

CSTL

SPRO

CTMX
Grifols Stock Declines After Brookfield Drops Buyout Offer

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Zacks last month

GRFS

BAM

SPRO
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s we

GlobeNewswire last month

CTMX
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.

Zacks last month

AZN

CSTL

CTMX
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.

Zacks last month

CTMX

SPRO

CSTL
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks last month

GRFS

BAM

CTMX
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

CTMX
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.

Zacks last month

AZN

SPRO

CSTL
CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

CytomX Therapeutics ( NASDAQ:CTMX ) Third Quarter 2024 Results Key Financial Results Revenue: US$33.4m (up 27% from 3Q...

Simply Wall St. 2 months ago

CTMX

Performance Overview

Return	6C1.SG	S&P 500
YTD	-15.77%	-1.35%
1-Year	-40.44%	+22.51%
3-Year	-75.79%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CytomX Therapeutics Inc (6C1.SG)

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Grifols Stock Declines After Brookfield Drops Buyout Offer

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Performance Overview